

MARKET REPORT



Multiple Myeloma: KOL Insight [2017]

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma: KOL Insight [2017]

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma: KOL Insight [2017]

Will novel therapies transform the treatment of Multiple Myeloma?

In recent years, there has been significant progress in the prognosis for newly diagnosed multiple myeloma (MM) patients. While the current range of treatment options – such as Celgene’s Revlimid and Takeda’s Velcade, and combination regimens of various therapies – are well established, unmet needs persist in the market for safe and effective drugs that can deliver durable treatment responses. Sanofi’s isatuximab, AbbVie/Roche’s venetoclax and Karyopharm Therapeutics’ selinexor form part of a rich late-stage pipeline, but which candidates stand out to key opinion leaders (KOLs)? Which products and combinations are likely to succeed? Learn how KOLs see the MM market evolving in KOL Insight: Multiple Myeloma (MM). Twelve US and European KOLs provide candid insights on 5 marketed and 8 pipeline therapies targeting various aspects of the MM treatment algorithm.

Take a tour of the report now:

Methodology >

Research Objectives >

Questions Asked >

See the Multiple Myeloma therapies covered >

Find out who the 6 US and 6 European KOLs are >

Sample Pages >

Top Takeaways

Can Amgen’s Kyprolis displace Velcade (Takeda/J&J) as the protease inhibitor (PI) of choice? Kyprolis is gaining ground, but what do KOLs think about its chances as the front-line option?

Is Farydak’s (Novartis) future in the MM therapeutic strategy tenable? Farydak’s position in the treatment algorithm remains uncertain. Can it maintain its position? KOLs provide their views.

Will PharmaMar/Chugai’s Aplidin (plitidepsin) reach the market? A marketing authorisation application has been submitted for plitidepsin in Europe, but how do experts rate the potential of this VEGF-R down-regulator?

What potential do KOLs think anti-PD-1 agents have in MM? Will Keytruda (Merck & Co) and Opdivo (Bristol-Myers Squibb) find a place in the treatment algorithm?

How do KOLs rate CheckMate 602? Empliciti, Opdivo, Pomalyst (Celgene) and dexamethasone regimen is being investigated in rrMM patients. Could lack of a PI be problematic?

Will Sanofi’s isatuximab be as effective as J&J’s Darzalex? Darzalex enjoys first-to-market advantage but can isatuximab challenge its position? What role will isatuximab have in the rrMM setting?

Could Array BioPharma’s filanesib, a KIF11 protein inhibitor, provide benefit in MM? KIF11 protein provides a

<https://www.bioportfolio.co.uk/product/107180>
pdb@bioportfolio.co.uk to order

novel target, but can it become a viable option or fall by the wayside?

Will AbbVie/Roche's venetoclax be restricted to Bcl-2 positive patients or could it have wider application? See how experts rate venetoclax and which combinations with the drug excite them?

What do KOLs think about Karyopharm's selinexor, the novel exportin-1 protein inhibitor? Will selinexor replicate its early promise in the larger Phase III BOSTON study?

Quotes

"When I consider the remedies available - or becoming available in the last one to three years - there are a lot of unmet needs; but I think we are on the way to convert Multiple myeloma from a malignant disease into a chronic disease." EU Key Opinion Leader

"The high-risk patients are still having a very poor survival, so although MM in general has a significant improvement in survival with all the new agents that we have, I think we are still lagging behind significantly in the number of patients with high-risk cytogenetics that lead to progression and early death." EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

Dazarlex (daratumumab; Genmab/Janssen Biotech)

Empliciti (elotuzumab; AbbVie/BMS)

Farydak (panobinostat; Novartis)

Kyprolis (carfilzomib; Onyx (Amgen))

Ninlaro (ixazomib; Takeda)

Pipeline Therapies

Encorafenib (Array BioPharma)

Filanesib (Array Biopharma)

Isatuximab (Sanofi)

Nivolumab (Opdivo; Bristol-Myers Squibb)

Pembrolizumab (Keytruda; Merck & Co.)

Plitidepsin (Aplidin; PharmaMar/Chugai (Roche))

Selinexor (Karyopharm Therapeutics)

Venetoclax (AbbVie/Roche)

Sample of KOLs interviewed

KOLs from North America

Prof. Guido Tricot, MD, PhD. Director of Holden Cancer Centre's Bone Marrow Transplant and Myeloma Program and Clinical professor, University of Iowa, IA, USA.

Prof. C. Ola Landgren, MD, PhD. Hematologic Oncologist, Chief and Professor of Medicine, Memorial Sloan Kettering Cancer Centre, New York, USA.

Prof. Irene Ghobrial, MD. Clinical Professor of Internal Medicine, Dana Farber Cancer Institute, Boston, USA.

Prof. Kenneth Anderson, MD. Kraft Family Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School and Brigham and Women's Hospital, Boston, USA.

Prof. Carol Ann Huff, MD. Associate Professor of Oncology and Medicine, Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Centre in Baltimore. USA.

Dr. Robert Schlossman, MD. Assistant Professor of Medicine, Dana-Farber / Harvard Cancer Institute, Harvard Medical School, Boston, USA.

KOLs from Europe

Dr Alberto Rocci, MD. Consultant haematologist, Manchester Royal Infirmary, Manchester, UK.

Dr. Charalampia Kyriakou, MD, PhD. Haematology consultant. Royal Free London NHS Foundation Trust and The North West London Hospitals NHS Trust, Northwick Park Hospital, UK.

Dr. Nicolas Blin, MD. Consultant, Department of Hematology. Nantes University Hospital, France.

Dr. Felicetto Ferrara, MD. Medical specialist in Hematology and Chief of the Hospital, Division of Hematology, Cardarelli Hospital, Napoli, Italy.

Anonymous German KOL, Dr. med., Head of Hematology, Research Group leader, Head of Quality Management. University Hospital Nuremberg-Erlangen, Germany.

Anonymous German KOL, Dr. med., Professor of medicine, Head of Oncology and Hematology department, Academic Teaching Hospital Mainz, Germany.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with a Physician survey offering a real commercial advantage.

Your Therapy Trends Report purchase entitles you to receive a Physician survey on key developments in the

<https://www.bioportfolio.co.uk/product/107180>
pdb@bioportfolio.co.uk to order

CAR-T field at 6 months following publication, which is published approximately 6 months following the report's publication date.

You will receive a copy of the Physician survey once available.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Additional Details

Publisher : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :



FirstWord

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Multiple Myeloma: KOL Insight [2017] [Report Updated: 01-07-2017]

- 1. Executive Summary 2. Research objectives 3. Research focus 3.1 Multiple myeloma treatment 3.2 Darzalex and Emluciti, the first mAbs on the MM scene 4. Marketed therapies 4.1 Overview 5. Proteasome inhibitors 5.1 Overview 5.1.1 Kyprolis (carfilzomib; Onyx (Amgen)) 5.1.2 Ninlaro (ixazomib; Takeda) 6. HDAC inhibitors 6.1 Overview 6.1.1 Farydak (panobinostat; Novartis) 7. Monoclonal antibodies 7.1 Overview 7.1.1 Darzalex (daratumumab; Genmab/Janssen Biotech) 7.1.2 Emluciti (elotuzumab; AbbVie/Bristol-Myers Squibb) 8. Pipeline therapies 8.1 Overview 9. Vascular endothelial growth factor-receptor antagonists 9.1 Overview 9.1.1 Aplidin (plitidepsin; PharmaMar/Chugai) 10. Programmed death receptor-1 inhibitors 10.1 Overview 10.1.1 Keytruda (pembrolizumab; Merck & Co.) 10.1.2 Opdivo (nivolumab; Bristol-Myers Squibb) 11. CD38 antigen inhibitors 11.1 Overview 11.1.1 Isatuximab (Sanofi) 12. Kinesin family member 11 (KIF11) protein inhibitors 12.1 Overview 12.1.1 Filanesib (Array BioPharma) 13. Apoptosis stimulant/proto-oncogene protein c-bcl-2 inhibitors 13.1 Overview 13.1.1 Venetoclax (Venclexta/Venclyxto; AbbVie/Roche) 14. Exportin-1 protein inhibitor/nuclear export inhibitors 14.1 Overview 14.1.1 Selinexor (Karyopharm Therapeutics) 15. Conclusion 15.1 Current and future treatment algorithm 16. Appendix 16.1 KOL details 16.1.1 KOLs from North America 16.1.2 KOLs from the EU

How to Buy...

Multiple Myeloma: KOL Insight [2017] [Report Updated: 01-07-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/107180>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

\$8145 | Single User Price

\$21095 | Global License Price

Payment Options: (please tick one)

Online Credit Card (we will email you the invoice with a payment link)

Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.